Dialog Box


Sydney Patient & Carer Education Day - World Expert coming to Australia   


Don't miss the chance to join us to learn more from a world expert on Non - Hodgkin Follicular Lymphoma - Professor Mathias Rummel.

This session is for patients, carers and interested health professionals and there will be an opportunity to have your questions answered If you live in Sydney (or nearby) please join us.

When - Saturday 30th March, 2019 

Where - Saxons Education Centre, Level 10 , 10 Barrack St, Sydney NSW 2000

Time - 1pm to 3pm (there will be tea and coffee available on arrival from 12.30pm)

The presentation will focus on:

  • Current frontline and relapsed treatments for follicular lymphoma
  • What is new for follicular lymphoma
  • Clinical Trials
  • Your Questions Answered  

About Professor Mathias Rummel 

Mathias Rummel, MD, is a Professor of Medicine and is the director of the Department for Haematology at the Clinic for Haematology and Medical Oncology at the Justus-Liebig University-Hospital in Giessen, Germany.

His current research focuses on novel treatment approaches in haematological malignancies, most notably Follicular Lymphoma, Mantle Cell Lymphoma, Waldenstrom’s Macroglobulinemia and other indolent lymphomas as well as Chronic Lymphocytic Leukemia (CLL), Hairy Cell Leukemia and also in the non-malignant haematological disorder Immune Thrombocytopenia (ITP).

He is the chair of the large cooperative German Study group indolent Lymphomas (StiL) with more than 220 study sites in Germany and Austria and is the principal investigator of several on-going clinical protocols, in particular of Investigator Initiated Trials (IIT).

Professor Rummel is actively involved in a number of professional scientific societies, including the American Society of Haematology (ASH), American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the European Haematology

Association (EHA), and the German Society of Haematology and Oncology (DGHO). He is the principal investigator of many clinical trials in Leukemias, Lymphomas, Hairy Cell Leukemia, and Immune Thrombocytopenia (ITP), and has published several book chapters and papers in peer reviewed scientific journals